Health, News, Trending

Demand Rises Nationwide for New HIV Prevention Injection Ahead of Rollout

Published by Samuel Ayomide on March 22nd, 2026.

As at March 22, 2026, Interest is rapidly growing across Nigeria for Lenacapavir, a newly introduced injectable medication designed to prevent Human Immunodeficiency Virus (HIV), as citizens begin seeking access ahead of its official nationwide rollout.

Investigations show that individuals, particularly those familiar with pre exposure prophylaxis, are already approaching health facilities and non governmental organisations in several states to inquire about the drug. According to Sunday Punch, this surge in demand comes as the Federal Government begins phased deployment of the twice yearly injection in selected pilot locations.

Lenacapavir, developed by Gilead Sciences, has been endorsed by the World Health Organisation (WHO) as an additional HIV prevention option, offering a long acting alternative to daily oral medication. The global health body’s recommendation in 2025 marked a significant step in expanding prevention strategies, as noted by The Guardian Nigeria.

Current data from the National Agency for the Control of AIDS (NACA) and the Joint United Nations Programme on HIV and AIDS (UNAIDS) indicate that nearly two million Nigerians are living with HIV. In response, the Federal Government, through the National HIV, Viral Hepatitis and STDs Control Programme, recently confirmed the arrival of initial doses of the injectable drug, with plans for wider distribution. A total of 52,000 doses are expected, with over 11,000 already delivered, according to Daily Times.

The rollout will begin in selected states including Lagos, Kano, Benue, Anambra, and others, alongside the Federal Capital Territory. Health officials say preparations are underway, including the training of medical personnel to ensure proper administration at designated public health facilities.

Despite the drug not yet being available in pharmacies, reports indicate strong demand in states such as Osun, Anambra, and Benue. A representative of the Network of People Living with HIV and AIDS in Nigeria (NEPWHAN) revealed that many individuals, particularly those in discordant relationships, are actively requesting the injection due to its preventive benefits.

“People are already asking for it in large numbers, especially those who understand its role in prevention,” the official said, noting that awareness within the HIV community has contributed significantly to the rising interest.

In Anambra, a health worker confirmed that initial supplies have arrived and are being distributed to selected facilities, although misconceptions remain. “Some people mistakenly believe it is a cure for HIV, but it is strictly preventive,” she explained, a concern also echoed by The Nation.

Health authorities have continued to emphasise that Lenacapavir does not treat HIV but works to prevent infection in individuals who are not already infected. Experts also note that it is currently approved for use among non pregnant individuals, with further studies ongoing.

Civil society groups and public health advocates have described the injectable as a major advancement in HIV prevention, particularly for high risk populations. They argue that its twice yearly administration could improve adherence compared to daily pills, thereby reducing new infections over time.

However, pharmacists have urged caution amid the excitement. The President of the Pharmaceutical Society of Nigeria (PSN), Ayuba Tanko, stressed that while the innovation is promising, regulatory processes must not be overlooked. According to him, agencies such as NAFDAC must complete thorough safety and efficacy evaluations before full scale deployment, as reported by The Guardian Nigeria.

Meanwhile, some states have begun preparing infrastructure for access. In Akwa Ibom, officials have identified multiple health centres for distribution once supplies arrive, while Kwara State has already made the injection available at selected facilities for eligible residents, Daily Times reports.

Public health experts believe that if properly implemented, the introduction of Lenacapavir could significantly strengthen Nigeria’s HIV prevention efforts. Still, they stress the importance of sustained awareness campaigns to address misconceptions and ensure the drug is used appropriately.

As anticipation builds nationwide, stakeholders say the success of the rollout will depend on effective coordination, public education, and continued investment in the country’s healthcare system.